论文部分内容阅读
近年来他汀类药物已被广泛应用于各类型高脂血症患者的调脂治疗。斯堪的纳维亚辛伐他汀存活试验(4S)、WOS、全国哮喘患病情况及相关危险因素流行病学调查(CARE)、LIPID及AFCAPD/TAXCAPS等研究均证实了他汀类药物卓越的降低密度脂蛋白胆固醇(low-density lipoprotein cholesterol,LDL-C)作用,其能有效降低心血管疾病的发病率和病死率。他汀类药物作为当前防治高胆固醇血症和动脉粥样硬化性疾病的首选药物,是调脂、防治心血管疾病的基石。
In recent years, statins have been widely used in various types of patients with hyperlipidemia lipid-lowering treatment. The Scandinavian Simvastatin Survival Trial (4S), WOS, the National Epidemiological Survey of Asthma and Relevant Risk Factors (CARE), LIPID and AFCAPD / TAXCAPS all demonstrated superior statin lowering Low-density lipoprotein cholesterol (LDL-C) effect, which can effectively reduce the incidence of cardiovascular disease and mortality. As the current drug of choice for the prevention and treatment of hypercholesterolemia and atherosclerotic diseases, statins are the cornerstone of lipid regulation and prevention and treatment of cardiovascular diseases.